Cadence discovery: study protocol for a dose-finding and mechanism of action clinical trial of sodium benzoate in people with treatment-refractory schizophrenia.

Abstract

BACKGROUND:

Schizophrenia is a persistent psychotic disorder often accompanied by severe disability and premature mortality. New pharmacological treatments are urgently needed. Sodium benzoate, a common food preservative holds potential to be an effective, accessible treatment for schizophrenia, though the optimal dosing and mechanism of action of the compound requires further investigation.

METHODS:

Individuals with persistent treatment-refractory schizophrenia (n=52) will be recruited. Patients will be randomised in a 1:1:1:1 ratio to receive treatment of one of three active doses (1000, 2000 or 4000 mg daily) of sodium benzoate or placebo for 6 weeks duration. The primary outcome measurement is change in the Positive and Negative Syndrome Scale (PANSS) total score. Secondary outcome measurements are PANSS subscales, Global Assessment of Function (GAF), Clinical Global Impression (CGI) and Patient Global Impression (PGI-I). Change in concentrations of peripheral amino acids (D-alanine, L-alanine, D-serine, L-serine, glycine and glutamate), plasma sodium benzoate, plasma catalase, 3-nitrotyrosine, malondialdehyde and high-sensitivity C-reactive protein (hs-CRP) will be determined as tertiary measures.

DISCUSSION:

This trial seeks to build upon previous research indicating potential efficacy of sodium benzoate for reduction of symptoms in individuals with treatment-refractory schizophrenia. The trial aims to improve the understanding of the mechanism of action of the compound.

TRIAL REGISTRATION:

Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12621000327886 . Registered on 23 March 2021.

• Authors: Andrea Baker, Lachlan Clarke, Peter Donovan, Jacobus P J Ungerer, Gunter Hartel, George Bruxner, Luca Cocchi, Anne Gordon, Vikas Moudgil, Gail Robinson, Digant Roy, Ravinder Sohal, Emma Whittle, James G Scott
• Journal: Trials (Trials) Vol. 22 Issue 1 Pg. 918 (Dec 13 2021) ISSN: 1745-6215 [Electronic] England
• PMID: 34903265 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s).

Chemical References

• Antipsychotic Agents
• Sodium Benzoate

Topics

• Antipsychotic Agents (adverse effects)
• Australia
• Double-Blind Method
• Humans
• Schizophrenia (diagnosis, drug therapy)
• Schizophrenia, Treatment-Resistant
• Sodium Benzoate (adverse effects)
• Treatment Outcome